Journal of Liver Cancer

Review Articles

Radioembolization for hepatocellular carcinoma: what clinicians need to know: Jin Woo Choi, Hyo-Cheol Kim; J Liver Cancer. 2022;22(1):4-13. Published online February 23, 2022; DOI: https://doi.org/10.17998/jlc.2022.01.16

30,441 Views
881 Downloads
29 Citations

Transarterial radioembolization (TARE) with yttrium 90 (⁹⁰Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea. There are two types of ⁹⁰Y radioactive microspheres available, namely, glass and resin microspheres, with comparable clinical outcomes. In general, TARE outperforms transarterial chemoembolization regarding post-embolization syndrome, time to progression, tumor downsizing for liver transplantation, and hospitalization stay. Although TARE is commonly recommended for patients with unresectable large HCCs, it can be an alternative to or performed in combination with ablation, surgical resection, and systemic treatment. This review aimed to address ⁹⁰Y radioactive microspheres, patient selection, clinical outcomes, simulation tests, radioembolization procedures, follow-up imaging, and complications.

Citations

Citations to this article as recorded by

The hepatic arterial system variations: A systematic review with meta-analysis
Adrian Balcerzak, George Triantafyllou, Fotis Demetriou, Maria Piagkou, Łukasz Olewnik
Annals of Anatomy - Anatomischer Anzeiger.2026; 263: 152752. CrossRef
The State of the Art in Combination Locoregional and Systemic Treatment Strategies for Hepatocellular Carcinoma: Recent Advancements and Future Horizons
Farbod Fazlollahi, Arianna D. Carfora, Marshal King, Elizabeth S. Wrasman, Mina S. Makary
Current Oncology.2026; 33(3): 172. CrossRef
Exploring Microalgae as a Novel Resource for Hepatocellular Carcinoma Therapy
Sik Yoon, Kok Keong Tan, Won Hoon Song, Chang Won Kim, Boon Huat Bay, Sae-Ock Oh
Molecules.2026; 31(6): 1033. CrossRef
Comparison of 166Holmium and 90Yttrium TARE in Hepatocellular Carcinoma Treatment
Emirhan Harbi, Hamza Ugur Bozbey, Utku Mahir Yildirim, Oral Oncul, Didem Tastekin
Clinical Nuclear Medicine Open.2026;[Epub] CrossRef
Hepatocellular Carcinoma Bridging and Downstaging: Advances in Locoregional Therapy
Elliott L. Fite, Nikhil Sekar, Jenish S. Venancius, Mina S. Makary
Biomedicines.2026; 14(4): 877. CrossRef
Effectiveness and Safety of Transarterial Radioembolization Following Inferior Phrenic Artery Glue Embolization for Flow Redistribution in Hepatocellular Carcinoma
Gun Ha Kim, Jeongyeon Kim, Eunbyeol Ko, Minyoung Oh, Changhwan Sung, Jin Hyoung Kim, Dong Il Gwon
Journal of Vascular and Interventional Radiology.2026; 37(7): 108784. CrossRef
Efficacy and safety of boosted transarterial radioembolization in patients with chemoembolization-refractory hepatocellular carcinoma
Gun Ha Kim, Eunbyeol Ko, Jeongyeon Kim, Minyoung Oh, Changhwan Sung, Jin Hyoung Kim, Dong Il Gwon
Acta Radiologica.2026;[Epub] CrossRef
Advances and Emerging Techniques in Y-90 Radioembolization for Hepatocellular Carcinoma
Elliott L. Fite, Mina S. Makary
Cancers.2025; 17(9): 1494. CrossRef
Eco-Friendly Approaches in Oncology: Developing Holmium (166Ho) Glass Microspheres for Hepatocellular Radioembolization
Sara Rhaissa Rezende dos Reis, Natália Cristina Gomes-da-Silva, Luciana Magalhães Rebelo Alencar, Alan Silva de Menezes, Frederico Duarte de Menezes, Kirill S. Golokhvast, Eduardo Ricci-Junior, Ralph Santos-Oliveira
ACS Omega.2025; 10(22): 22426. CrossRef
Hepatocellular Carcinoma: Review of Indian Literature
Vaishnavi Konda, Shanthi Vijayaraghavan
Gastroenterology, Hepatology and Endoscopy Practice.2025; 5(3): 95. CrossRef
Comparative Evaluation of Intraarterial Therapy Methods for Hepatocellular Cancer
A. P. Petrosyan, V. V. Kucherov, Yu. A. Emelyanova, A. D. Kaprin, S. A. Ivanov, L. O. Petrov, N. A. Falaleeva, A. G. Isaeva, A. S. Dikova, A. T. Stekhova, E. A. Volicheva
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2025; 35(2): 45. CrossRef
LI-RADS TRA V2024: innovations in imaging assessment of hepatocellular carcinoma response to locoregional therapies
Alexandre Key Wakate Teruya, Joao Miranda, Hilton Leão Filho, Daniel Lahan-Martins, Cassia Tamura Sttefano Guimaraes, Roberto Blasbalg, Fernanda Garozzo Velloni
Abdominal Radiology.2025; 51(3): 1289. CrossRef
Assessment of Preprocedural Factors Associated with 5-Year Complete Response After Transarterial Radioembolization in Patients with Hepatocellular Carcinoma
June Park, Dong Kyu Kim, Seungsoo Lee, Shin Hye Hwang
Diagnostics.2025; 15(18): 2297. CrossRef
Radioembolization for hepatocellular carcinoma
Yoselin Dos Santos Poleo, Abrahams Ocanto Martínez
Revisiones en Cáncer.2025;[Epub] CrossRef
Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150
Masatoshi Kudo, Tatsuya Yamashita, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann-Lii Cheng, Kaoru Tsuchiya, Naoya Sakamoto, Shuhei Hige, Ryosuke Take, Kyoko Yamada, Yuki Nakagawa, Hayato Takahashi, Masafumi Ikeda
Liver Cancer.2025; 14(5): 539. CrossRef
Unlocking Precision in Radioembolization: Navigating the Future of Holmium-166 Radioembolization Mapping and Lung Shunt Study by Implementing Scout Dosimetry
Peiman Habibollahi, Armeen Mahvash, Nima Kokabi, Nariman Nezami
CardioVascular and Interventional Radiology.2024; 47(4): 451. CrossRef
Feasibility of Liver Transplantation after 90Y Radioembolization: Lessons from a Radiation Protection Incident
Marine Soret, Jacques-Antoine Maisonobe, Philippe Maksud, Stéphane Payen, Manon Allaire, Eric Savier, Charles Roux, Charlotte Lussey-Lepoutre, Aurélie Kas
Health Physics.2024; 127(3): 373. CrossRef
Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management
Cody R. Criss, Mina S. Makary
Current Oncology.2024; 31(4): 2076. CrossRef
Selective internal radiation therapy segmentectomy: A new minimally invasive curative option for primary liver malignancies?
Riccardo Inchingolo, Francesco Cortese, Antonio Rosario Pisani, Fabrizio Acquafredda, Roberto Calbi, Riccardo Memeo, Fotis Anagnostopoulos, Stavros Spiliopoulos
World Journal of Gastroenterology.2024; 30(18): 2379. CrossRef
Transarterial radioembolization vs transarterial chemoembolization with drug-eluting beads for treating hepatocellular carcinoma: a cost-effectiveness analysis in Japanese healthcare system
Go Shirota, So Sato, Hideo Yasunaga, Shotaro Aso, Masaaki Akahane, Daisuke Itoh, Osamu Abe
Japanese Journal of Radiology.2024; 42(12): 1501. CrossRef
Combining liver-directed and immunotherapy in advanced hepatocellular carcinoma: A review and future directions
Pranav Kumar, Chase J. Wehrle, Keyue Sun, Chunbao Jiao, Rebecca Panconesi, Mingyi Zhang, Noah X. Tocci, Hanna Hong, Abby Gross, Erlind Allkushi, Maureen Whitsett Linganna, Andrea Schlegel, Toms Augustin, Charles Miller, David CH Kwon, Kazunari Sasaki, Fed
Surgical Oncology Insight.2024; 1(4): 100100. CrossRef
Advances in Understanding Hepatocellular Carcinoma Vasculature: Implications for Diagnosis, Prognostication, and Treatment
Hyungjin Rhee, Young Nyun Park, Jin-Young Choi
Korean Journal of Radiology.2024; 25(10): 887. CrossRef
Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma
Kelly Hao, Andrew J Paik, Lauren H Han, Mina S Makary
World Journal of Radiology.2024; 16(10): 512. CrossRef
Radiation Safety Assessment of 177Lu-DOTATATE Intra-arterial Peptide Receptor Therapy (PRRT)
Manoj Kumar Hariram Chauhan, Ashish Kumar Jha, Sneha Mithun, Rutuja Dasharath Parab, Pooja Dwivedi, Ameya D Puranik, Kunal Bharat Gala, Nitin Sudhakar Shetye, Suyash Kulkarni, Venkatesh Rangarajan
Indian Journal of Nuclear Medicine.2024; 39(4): 254. CrossRef
Transarterial chemoembolization as an alternative to radioembolization is associated with earlier tumor recurrence than in radioembolization-eligible patients
Sung Won Chung, Heejin Cho, Hyunjae Shin, Jeayeon Park, Ju Yeon Kim, Ji Hoon Hong, Moon Haeng Hur, Min Kyung Park, Yun Bin Lee, Su Jong Yu, Myungsu Lee, Yoon Jun Kim, Jin Chul Paeng, Jung-Hwan Yoon, Jin Wook Chung, Jeong-Hoon Lee, Hyo-Cheol Kim
Frontiers in Oncology.2023;[Epub] CrossRef
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review
Brandon M. Meyers, Jennifer J. Knox, David M. Liu, Deanna McLeod, Ravi Ramjeesingh, Vincent C. Tam, Howard J. Lim
Cancer Treatment Reviews.2023; 118: 102584. CrossRef
Recent Advances in Image-Guided Locoregional Therapies for Primary Liver Tumors
Cody R. Criss, Mina S. Makary
Biology.2023; 12(7): 999. CrossRef
Multidisciplinary consensus recommendations for management of hepatocellular carcinoma in Middle East and North Africa region
Imam Waked, Sherif Alsammany, Sayed Hammad Tirmazy, Kakil Rasul, Jafar Bani‐Issa, Wael Abdel‐Razek, Ashraf Omar, Amr Shafik, Salem Eid, Amr Abdelaal, Ahmed Hosni, Gamal Esmat
Liver International.2023; 43(10): 2062. CrossRef
Impact of Low Skeletal Muscle Mass on Long-Term Outcomes in Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization: A Retrospective Multi-Center Study
Heechul Nam, Hyun Yang, Ho Soo Chun, Han Ah Lee, Joon Yeul Nam, Jeong Won Jang, Yeon Seok Seo, Do Young Kim, Yoon Jun Kim, Si Hyun Bae
Cancers.2023; 15(21): 5195. CrossRef

Transarterial Approach in Early Stage HCC: From Palliative Therapy to Curative Therapy: Jung Suk Oh, Ho Jong Chun; Journal of the Korean Liver Cancer Study Group. 2012;12(2):93-96. Published online September 30, 2012

1,274 Views
6 Downloads

Abstract PDF: Early stage hepatocellular carcinoma (HCC) based on BCLC staging system can be curatively treated by liver transplantation, surgical resection or percutaneous ablation. However, transarterial approaches, including transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), are standard of care for intermediate stage HCC and can be an alternative treatment in the patients with early stage HCC which are unresectable, unsuitable for percutaneous ablation, or not eligible for liver transplantation. Many previous TACE studies in early stage HCC revealed that the overall survival rate was competitive with those of curative therapies considering their operation risks, but recurrence-free survival rate was significantly lower than curative therapies. Moreover, the histopathologic reports about TACE in early stage HCC demonstrated that only 38% of the HCC nodules were completely necrotic after TACE and only 81% of the nodules with complete response by EASL criteria showed complete necrosis. Although there is no long-term survival data about TARE in early stage HCC, a histopathologic report about TARE showed that 73% of the HCC nodules were completely necrotic after TARE and 100% of the nodules with complete response by EASL criteria showed complete necrosis. In conclusion, TACE is now limited to be categorized into a curative therapy in early stage HCC, according to the previous data about TACE. However, new recent technologies including C-arm CT, superselective embolization technique, drug-eluting bead (DEB) may sufficiently improve the survival data of TACE to prove its curative role. Considering its RFA-comparable histopathologic tumor response, TARE may prove to be a potential curative therapeutic for early stage HCC.

First
Prev
Page of 1
Next
Last

Search